{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T08:23:37Z","timestamp":1790497417952,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Programme Hospitalier de Recherche Clinique","award":["ISRCTN10059974"],"award-info":[{"award-number":["ISRCTN10059974"]}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.ejca.2017.01.008","type":"journal-article","created":{"date-parts":[[2017,3,7]],"date-time":"2017-03-07T08:46:38Z","timestamp":1488876398000},"page":"323-332","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["Long-term outcome of the REMAGUS 02 trial, a multicenter randomised phase II trial in locally advanced breast cancer\u00a0patients treated with neoadjuvant chemotherapy with or without celecoxib or trastuzumab according to HER2 status"],"prefix":"10.1016","volume":"75","author":[{"given":"Sylvie","family":"Giacchetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Sophie","family":"Hamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzette","family":"Delaloge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0881-9371","authenticated-orcid":false,"given":"Etienne","family":"Brain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3251-4060","authenticated-orcid":false,"given":"Fr\u00e9d\u00e9rique","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Sigal-Zafrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Christine","family":"Mathieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Bertheau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Marc","family":"Guinebreti\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahasti","family":"Saghatchian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Lerebours","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"chafouny","family":"mazouni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Tembo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Espi\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabien","family":"Reyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Marty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Asselain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Yves","family":"Pierga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2017.01.008_bib1","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1200\/JCO.2007.15.0235","article-title":"Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27","volume":"26","author":"Rastogi","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2017.01.008_bib2","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1093\/jnci\/dji021","article-title":"Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis","volume":"97","author":"Mauri","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2017.01.008_bib3","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1002\/bjs.5894","article-title":"Neoadjuvant chemotherapy for operable breast cancer","volume":"94","author":"Mieog","year":"2007","journal-title":"Br J Surg"},{"key":"10.1016\/j.ejca.2017.01.008_bib4","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1245\/s10434-011-1877-y","article-title":"Neoadjuvant chemotherapy is associated with improved survival compared with adjuvant chemotherapy in patients with triple-negative breast cancer only after complete pathologic response","volume":"19","author":"Fisher","year":"2012","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejca.2017.01.008_bib5","doi-asserted-by":"crossref","first-page":"219869","DOI":"10.1155\/2013\/219869","article-title":"Neoadjuvant therapy in operable breast cancer: application to triple negative breast cancer","volume":"2013","author":"Ademuyiwa","year":"2013","journal-title":"J Oncol"},{"issue":"Suppl. 2","key":"10.1016\/j.ejca.2017.01.008_bib6","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1016\/j.breast.2015.07.018","article-title":"Neoadjuvant treatment of breast cancer\u2013clinical and research perspective","volume":"24","author":"Loibl","year":"2015","journal-title":"Breast"},{"key":"10.1016\/j.ejca.2017.01.008_bib7","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2017.01.008_bib8","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.1200\/JCO.2007.10.6823","article-title":"Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy","volume":"25","author":"Symmans","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2017.01.008_bib9","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1200\/JCO.2011.38.8595","article-title":"Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes","volume":"30","author":"von Minckwitz","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2017.01.008_bib10","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s10549-010-0939-3","article-title":"A multicenter randomized phase II study of sequential epirubicin\/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients","volume":"122","author":"Pierga","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ejca.2017.01.008_bib11","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/00000421-199306000-00006","article-title":"Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate","volume":"16","author":"Chevallier","year":"1993","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ejca.2017.01.008_bib12","doi-asserted-by":"crossref","first-page":"5309","DOI":"10.1038\/onc.2014.475","article-title":"The origin of breast tumor heterogeneity","volume":"34","author":"Skibinski","year":"2015","journal-title":"Oncogene"},{"key":"10.1016\/j.ejca.2017.01.008_bib13","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/nrclinonc.2013.124","article-title":"Luminal breast cancer: from biology to treatment","volume":"10","author":"Ignatiadis","year":"2013","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ejca.2017.01.008_bib14","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/S1470-2045(14)70080-4","article-title":"Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort","volume":"15","author":"Gianni","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2017.01.008_bib15","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S1470-2045(11)70397-7","article-title":"Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial","volume":"13","author":"Untch","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2017.01.008_bib16","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S1470-2045(14)70320-1","article-title":"Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response","volume":"15","author":"de Azambuja","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2017.01.008_bib17","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(11)70336-9","article-title":"Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial","volume":"13","author":"Gianni","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2017.01.008_bib18","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S1470-2045(16)00163-7","article-title":"5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial","volume":"17","author":"Gianni","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2017.01.008_bib19","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1001\/jamaoncol.2015.6113","article-title":"Association of pathologic complete response to neoadjuvant therapy in HER2-positive breast cancer with long-term outcomes: a meta-analysis","volume":"2","author":"Broglio","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2017.01.008_bib20","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1200\/JCO.2005.02.6914","article-title":"Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors","volume":"24","author":"Guarneri","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2017.01.008_bib21","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1054\/bjoc.2000.1461","article-title":"Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer","volume":"83","author":"Pierga","year":"2000","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2017.01.008_bib22","doi-asserted-by":"crossref","first-page":"e0144359","DOI":"10.1371\/journal.pone.0144359","article-title":"Beyond axillary lymph node metastasis, BMI and menopausal status are prognostic determinants for triple-negative breast cancer treated by neoadjuvant chemotherapy","volume":"10","author":"Bonsang-Kitzis","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ejca.2017.01.008_bib23","doi-asserted-by":"crossref","first-page":"7098","DOI":"10.1200\/JCO.2005.11.124","article-title":"Factors predictive of distant metastases in patients with breast cancer who have a pathologic complete response after neoadjuvant chemotherapy","volume":"23","author":"Gonzalez-Angulo","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2017.01.008_bib24","doi-asserted-by":"crossref","first-page":"964","DOI":"10.3109\/0284186X.2016.1167955","article-title":"Pattern of relapse after breast conserving therapy, a study of 1519 early breast cancer patients treated in the Central Region of Denmark 2000\u20132009","volume":"55","author":"Bodilsen","year":"2016","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ejca.2017.01.008_bib25","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ejca.2014.11.023","article-title":"Tumour size is the only predictive factor of distant recurrence after pathological complete response to neoadjuvant chemotherapy in patients with large operable or locally advanced breast cancers: a sub-study of EORTC 10994\/BIG 1-00 phase III trial","volume":"51","author":"Fei","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2017.01.008_bib26","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/bjc.2015.426","article-title":"Pathological complete response and prognosis after neoadjuvant chemotherapy for HER2-positive breast cancers before and after trastuzumab era: results from a real-life cohort","volume":"114","author":"Hamy-Petit","year":"2016","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2017.01.008_bib27","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1038\/bjc.2014.81","article-title":"Long-term survival of advanced triple-negative breast cancers with a dose-intense cyclophosphamide\/anthracycline neoadjuvant regimen","volume":"110","author":"Giacchetti","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2017.01.008_bib28","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1093\/annonc\/mdv221","article-title":"Tailoring therapies\u2013improving the management of early breast cancer: St. Gallen international expert consensus on the primary therapy of early breast cancer 2015","volume":"26","author":"Coates","year":"2015","journal-title":"Ann Oncol"},{"issue":"Suppl. 6","key":"10.1016\/j.ejca.2017.01.008_bib29","article-title":"Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"24","author":"Senkus","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2017.01.008_bib30","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1200\/JCO.2012.43.4134","article-title":"Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal a breast cancer","volume":"31","author":"Prat","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2017.01.008_bib31","first-page":"1707","article-title":"Progesterone receptor loss identifies hormone receptor-positive and HER2-negative breast cancer subgroups at higher risk of relapse: a retrospective cohort study","volume":"9","author":"Sun","year":"2016","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.ejca.2017.01.008_bib32","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12885-015-1121-4","article-title":"Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer","volume":"15","author":"Bae","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejca.2017.01.008_bib33","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/nature14583","article-title":"Progesterone receptor modulates ERalpha action in breast cancer","volume":"523","author":"Mohammed","year":"2015","journal-title":"Nature"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980491730062X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980491730062X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,3]],"date-time":"2018-09-03T15:51:54Z","timestamp":1535989914000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095980491730062X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":33,"alternative-id":["S095980491730062X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2017.01.008","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term outcome of the REMAGUS 02 trial, a multicenter randomised phase II trial in locally advanced breast cancer\u00a0patients treated with neoadjuvant chemotherapy with or without celecoxib or trastuzumab according to HER2 status","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2017.01.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}